Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Chen Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-8155-773X; OpenAlex author ID A5100322131. Sources: OpenAlex.

Their work

Papers
78 (first author 5, last author 16)
Trials
0
Grants
0
Labs led
1
Collaborators
124
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 4 papers · 2014: 6 papers · 2015: 9 papers · 2016: 9 papers · 2017: 8 papers · 2018: 6 papers · 2019: 4 papers · 2020: 8 papers · 2021: 2 papers · 2022: 4 papers · 2023: 6 papers · 2024: 4 papers · 2025: 2 papers · 2026: 2 papers

Papers 50 of 78

  1. Comparative evaluation of chemotherapy and CAR-T cell therapy in genetically engineered self-sustaining primary pancreatic cancer organoids. Co-author DOI 10.1016/j.pan.2026.07.013↗
  2. Corrigendum to "Wang X, Wang R, Lin X et al. Comparative evaluation of chemotherapy and CAR-T cell therapy in genetically engineered self-sustaining primary pa… Co-author DOI 10.1016/j.pan.2026.09.001↗
  3. Assessment of tertiary lymphoid structures via 18F-FDG PET/CT scan in patients with pancreatic adenocarcinoma. Co-author DOI 10.1007/s00262-025-04205-x↗
  4. Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Tri… Co-author DOI 10.1097/sla.0000000000006681↗
  5. BCL6 overexpression in CD4+ T cells induces Tfh-like transdifferentiation and enhances antitumor efficiency of CAR-T therapy in pancreatic cancer. Last author DOI 10.1016/j.bbadis.2024.167346↗
  6. The GFPT2-O-GlcNAcylation-YBX1 axis promotes IL-18 secretion to regulate the tumor immune microenvironment in pancreatic cancer. Co-author DOI 10.1038/s41419-024-06589-7↗
  7. Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature. First author DOI 10.1097/cad.0000000000001546↗
  8. Efficacy of Hyperthermic Intraperitoneal Chemotherapy Alone for Diffuse Peritoneal Carcinomatosis from Pancreatic Adenocarcinoma: A Single-Centre Retrospective… Last author DOI 10.21203/rs.3.rs-4011964/v1↗
  9. Short-Term Outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.5210↗
  10. Glutamine is a substrate for glycosylation and CA19-9 biosynthesis through hexosamine biosynthetic pathway in pancreatic cancer. Co-author DOI 10.1007/s12672-023-00628-z↗
  11. Laparoscopic pancreaticoduodenectomy with portal or superior mesenteric vein resection and reconstruction for pancreatic cancer: A single-center experience. Last author DOI 10.1016/j.hbpd.2023.01.004↗
  12. Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic significance. Last author DOI 10.1136/jitc-2023-006698↗
  13. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12876-023-02748-w↗
  14. Expression Profiles of Cuproptosis-Related Genes Determine Distinct Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol30020126↗
  15. Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41389-022-00411-9↗
  16. Body Composition and Response and Outcome of Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1080/01635581.2020.1870704↗
  17. Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1155/2022/7353572↗
  18. TGF-β1-induced RAP2 regulates invasion in pancreatic cancer. First author DOI 10.3724/abbs.2022015↗
  19. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Co-author DOI 10.1016/j.bbcan.2020.188409↗
  20. High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12957-021-02147-z↗
  21. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. Last author DOI 10.1002/cam4.2895↗
  22. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2020.02.016↗
  23. HNF-1a promotes pancreatic cancer growth and apoptosis resistance via its target gene PKLR. Co-author DOI 10.1093/abbs/gmz169↗
  24. Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. Co-author DOI 10.1177/1073274820915947↗
  25. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13045-020-00958-3↗
  26. Prognostic Value of the C-Reactive Protein/Lymphocyte Ratio in Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08301-3↗
  27. ASO Author Reflections: C-Reactive Protein/Lymphocyte Ratio as a Promising Marker for Predicting Survival in Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08335-7↗
  28. Lewis antigen‑negative pancreatic cancer: An aggressive subgroup. Co-author DOI 10.3892/ijo.2020.4989↗
  29. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cance… Last author DOI 10.1002/cam4.2463↗
  30. Kras G12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer. Last author DOI 10.1016/j.canlet.2019.01.013↗
  31. Characteristics and Outcomes of Pancreatic Cancer by Histological Subtypes. Co-author DOI 10.1097/mpa.0000000000001338↗
  32. The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer. Last author DOI 10.2147/cmar.s211363↗
  33. Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00262-018-2235-8↗
  34. MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer. Last author DOI 10.1016/j.canlet.2018.01.017↗
  35. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2018.05.479↗
  36. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.08.003↗
  37. Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001073↗
  38. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. Co-author DOI 10.1186/s13045-017-0551-7↗
  39. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. First author DOI 10.1002/ijc.30650↗
  40. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype. First author DOI 10.1016/j.canlet.2016.10.046↗
  41. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2016.08.005↗
  42. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. First author DOI 10.1097/sla.0000000000001741↗
  43. Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer. Co-author DOI 10.1245/s10434-016-5579-3↗
  44. A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. Co-author DOI 10.3892/ijo.2017.3938↗
  45. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer. Co-author DOI 10.3892/ijo.2017.4032↗
  46. Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. Co-author DOI 10.3892/ol.2016.5501↗
  47. New insights into perineural invasion of pancreatic cancer: More than pain. Co-author DOI 10.1016/j.bbcan.2016.01.002↗
  48. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Last author DOI 10.1016/j.pan.2016.09.007↗
  49. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Co-author DOI 10.1016/j.pan.2016.09.013↗
  50. Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/m… Co-author DOI 10.1038/srep19222↗

Closest collaborators

The 25 strongest of 124 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 77 shared papers, 2011–2026 · strength 6.99
  2. Guopei Luo · 46 shared papers, 2011–2025 · strength 3.59
  3. He Cheng · 29 shared papers, 2016–2026 · strength 3.45
  4. Kaizhou Jin · 37 shared papers, 2015–2025 · strength 3.32
  5. Quanxing Ni · 39 shared papers, 2012–2023 · strength 2.55
  6. Jin Xu · 40 shared papers, 2011–2025 · strength 2.12
  7. Zhiyao Fan · 17 shared papers, 2018–2021 · strength 1.67
  8. Jiang Long · 35 shared papers, 2011–2018 · strength 1.66
  9. Yitao Gong · 14 shared papers, 2019–2022 · strength 1.58
  10. Yusheng Chen · 8 shared papers, 2022–2025 · strength 1.46
  11. Xu Wang · 8 shared papers, 2022–2025 · strength 1.39
  12. Liang Liu · 29 shared papers, 2013–2018 · strength 1.39
  13. Xuan Lin · 8 shared papers, 2022–2025 · strength 1.39
  14. Yunzhen Qian · 11 shared papers, 2020–2023 · strength 1.32
  15. Xuan Zou · 7 shared papers, 2022–2025 · strength 1.20
  16. Mingjian Ma · 5 shared papers, 2023–2025 · strength 0.98
  17. Zhengjie Dai · 6 shared papers, 2022–2024 · strength 0.97
  18. Meng Guo · 15 shared papers, 2014–2018 · strength 0.87
  19. Chao Yang · 10 shared papers, 2018–2020 · strength 0.84
  20. Yesiboli Tasiheng · 5 shared papers, 2022–2024 · strength 0.76
  21. Shunrong Ji · 12 shared papers, 2013–2025 · strength 0.75
  22. Zhiwen Xiao · 11 shared papers, 2012–2023 · strength 0.74
  23. Weiding Wu · 4 shared papers, 2021–2025 · strength 0.71
  24. Si Shi · 12 shared papers, 2012–2025 · strength 0.66
  25. Cheng He · 6 shared papers, 2015–2023 · strength 0.61

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.